{"name":"Telix Pharmaceuticals","slug":"telix-pharmaceuticals","ticker":"TLX.AX","exchange":"ASX","domain":"telixpharma.com","description":"Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with","hq":"Melbourne, Victoria, Australia","founded":0,"employees":"1120","ceo":"","sector":"Radiopharmaceuticals / Nuclear Medicine","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":14.85,"stockChange":0.33,"stockChangePercent":2.27,"marketCap":"$5.0B","metrics":{"revenue":803793984,"revenueGrowth":49.3,"grossMargin":47.5,"rdSpend":0,"netIncome":-7125000,"cash":141866000,"dividendYield":0,"peRatio":117.4,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"153Sm-DOTMP","genericName":"153Sm-DOTMP","slug":"153sm-dotmp","indication":"Prostate cancer","status":"phase_1"},{"name":"131I-IPA","genericName":"131I-IPA","slug":"131i-ipa","indication":"Prostate cancer","status":"phase_1"},{"name":"177Lu-DOTA-TLX591","genericName":"177Lu-DOTA-TLX591","slug":"177lu-dota-tlx591","indication":"Metastatic castration-resistant prostate cancer","status":"phase_2"},{"name":"177Lu-TLX591","genericName":"177Lu-TLX591","slug":"177lu-tlx591","indication":"Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression","status":"phase_3"},{"name":"64Cu-DOTA-TLX592","genericName":"64Cu-DOTA-TLX592","slug":"64cu-dota-tlx592","indication":"Neuroendocrine tumors","status":"phase_1"}]}],"pipeline":[{"name":"153Sm-DOTMP","genericName":"153Sm-DOTMP","slug":"153sm-dotmp","phase":"phase_1","mechanism":"A radioligand targeting somatostatin receptors","indications":["Prostate cancer","Neuroendocrine tumors"],"catalyst":""},{"name":"131I-IPA","genericName":"131I-IPA","slug":"131i-ipa","phase":"phase_1","mechanism":"Iodine-131 labelled peptide for targeted radionuclide therapy","indications":["Prostate cancer","Neuroendocrine tumors"],"catalyst":""},{"name":"177Lu-DOTA-TLX591","genericName":"177Lu-DOTA-TLX591","slug":"177lu-dota-tlx591","phase":"phase_2","mechanism":"177Lu-DOTA-TLX591 is a radiolabeled peptide that targets the prostate-specific membrane antigen (PSMA) for targeted alpha-particle therapy.","indications":["Metastatic castration-resistant prostate cancer"],"catalyst":""},{"name":"177Lu-TLX591","genericName":"177Lu-TLX591","slug":"177lu-tlx591","phase":"phase_3","mechanism":"177Lu-TLX591 is a lutetium-177 labeled radioligand that targets prostate-specific membrane antigen (PSMA) on prostate cancer cells to deliver targeted radiotherapy.","indications":["Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression"],"catalyst":""},{"name":"64Cu-DOTA-TLX592","genericName":"64Cu-DOTA-TLX592","slug":"64cu-dota-tlx592","phase":"phase_1","mechanism":"Somatostatin receptor targeting","indications":["Neuroendocrine tumors"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":5,"phaseCounts":{"phase_1":3,"phase_2":1,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":803794000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":803794000},{"period":"2024-12-31","value":516551000},{"period":"2023-12-31","value":332978000},{"period":"2022-12-31","value":108913288.977781}],"grossProfit":426438000,"grossProfitHistory":[{"period":"2025-12-31","value":426438000},{"period":"2024-12-31","value":336163000},{"period":"2023-12-31","value":209533000},{"period":"2022-12-31","value":64578146.046777}],"rdSpend":171249000,"rdSpendHistory":[{"period":"2025-12-31","value":171249000},{"period":"2024-12-31","value":127930000},{"period":"2023-12-31","value":85315000},{"period":"2022-12-31","value":54891356.109773}],"sgaSpend":237148000,"operatingIncome":18053000,"operatingIncomeHistory":[{"period":"2025-12-31","value":18053000},{"period":"2024-12-31","value":55584000},{"period":"2023-12-31","value":34965000},{"period":"2022-12-31","value":-50475529.613454}],"netIncome":-7125000,"netIncomeHistory":[{"period":"2025-12-31","value":-7125000},{"period":"2024-12-31","value":33685000},{"period":"2023-12-31","value":4208000},{"period":"2022-12-31","value":-104079000}],"eps":-0.0211,"epsHistory":[{"period":"2025-12-31","value":-0.0211},{"period":"2024-12-31","value":0.0976},{"period":"2023-12-31","value":0.010969},{"period":"2022-12-31","value":-0.2279}],"cash":141866000,"cashHistory":[{"period":"2025-12-31","value":141866000},{"period":"2024-12-31","value":439999000},{"period":"2023-12-31","value":84295000},{"period":"2022-12-31","value":116329000}],"totalAssets":1163986000,"totalLiabilities":748610000,"totalDebt":467106000,"equity":415376000,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":-43776000,"capexHistory":[{"period":"2025-12-31","value":-43776000},{"period":"2024-12-31","value":-22184000},{"period":"2023-12-31","value":-7109000},{"period":"2022-12-31","value":-9429636.583806}],"freeCashflow":-61069000,"dividendsPaid":null,"buybacks":-7816000,"employees":1120,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":14.85,"previousClose":14.52,"fiftyTwoWeekHigh":27.4,"fiftyTwoWeekLow":8.26,"fiftyTwoWeekRange":"8.26 - 27.4","fiftyDayAverage":13.53,"twoHundredDayAverage":13.64,"beta":0.65,"enterpriseValue":5356083200,"forwardPE":117.4,"priceToBook":8.38,"priceToSales":6.26,"enterpriseToRevenue":6.66,"enterpriseToEbitda":165.01,"pegRatio":0,"ebitda":32460000,"ebitdaMargin":4,"freeCashflow":-36673500,"operatingCashflow":-17293000,"totalDebt":467105984,"debtToEquity":112.5,"currentRatio":1.43,"returnOnAssets":1.1,"returnOnEquity":-1.9,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":11,"targetMeanPrice":23.34,"targetHighPrice":32,"targetLowPrice":18,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":17.3,"institutionHeldPercent":23.9,"sharesOutstanding":338777049,"floatShares":272563292,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":-0.03,"epsForward":0.13,"revenuePerShare":2.38,"bookValue":1.77,"officers":[{"age":49,"name":"Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.D","title":"Co-Founder, MD, Group CEO & Executive Director"},{"age":60,"name":"Mr. Darren  Smith B.Bus., FCPA, M.B.A.","title":"Group Chief Financial Officer"},{"age":52,"name":"Mr. Darren  Patti Pharm.D.","title":"Group Chief Operating Officer"},{"age":55,"name":"Dr. David N. Cade M.B.A., M.D., MBBS","title":"Group Chief Medical Officer"},{"age":null,"name":"Dr. Paul  Schaffer","title":"SVP of Research & Development"},{"age":null,"name":"Mr. Craig  Ulrick","title":"Chief Information Officer"},{"age":null,"name":"Ms. Kyahn  Williamson B.A.","title":"Senior Vice President of Corporate Communications & Investor Relations"},{"age":null,"name":"Mr. Christian  Krautkramer J.D.","title":"Group General Counsel"}],"industry":"Biotechnology","irWebsite":"","website":"https://telixpharma.com","phone":"61 3 9093 3855"}}